ESSA Pharma Inc.: ESSA Pharma Inc is a preclinical stage pharmaceutical company focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs which selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Selected a new lead candidate, EPI-7386 in March; showing a more favorable pharmacokinetic profile in mice, exhibiting significant exposure and a long half-life. The Company’s recent public offering, concurrent private placement, and Realm Therapeutics acquisition gives them a cash runway into 2023.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Disease Space
Oncology
Listing
Public, USA
Market Cap
<100MM
Website:
Address:
999 West Broadway Street Suite 720
Vancouver, British Columbia
Canada

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.